Immunocore Holdings plc Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Immunocore Holdings plc (IMCR) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $22.73 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-06
- Immunocore Holdings plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$8.90M, a 170.15% decline year-over-year.
- Immunocore Holdings plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $12.69M, a 96.75% decline year-over-year.
- Immunocore Holdings plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $391.00M, a 2758.78% increase year-over-year.
- Immunocore Holdings plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $13.68M.
- Immunocore Holdings plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$14.68M, a 199.11% decline from fiscal 2024.
- Immunocore Holdings plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $14.81M, a 53.51% decline from fiscal 2023.
- Immunocore Holdings plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $31.86M, a 66.12% decline from fiscal 2022.
- Immunocore Holdings plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $94.04M, a 34.61% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $22.73M 10-Q · filed 2026-08-06 | ||||
| 2026-03-31 | -$8.90M 10-Q · filed 2026-05-06 | ||||
| 2025-12-31 | -$14.68M 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | $14.57M 10-Q · filed 2025-11-06 | ||||
| 2025-06-30 | $11.91M 10-Q · filed 2026-08-06 | ||||
| 2025-03-31 | $12.69M 10-Q · filed 2026-05-06 | ||||
| 2024-12-31 | $14.81M 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | $83.81M 10-Q · filed 2025-11-06 | ||||
| 2024-06-30 | $63.32M 10-Q · filed 2025-08-07 | ||||
| 2024-03-31 | $391.00M 10-Q · filed 2025-05-07 | ||||
| 2023-12-31 | $31.86M 10-K · filed 2026-02-25 | $31.86M 10-K · filed 2024-02-28 | |||
| 2023-09-30 | $44.16M 10-Q · filed 2024-11-06 | ||||
| 2023-06-30 | $23.90M 10-Q · filed 2024-08-08 | ||||
| 2023-03-31 | $13.68M 10-Q · filed 2024-05-08 | ||||
| 2022-12-31 | $94.04M 10-K · filed 2025-02-26 | ||||
| 2021-12-31 | $143.80M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |